Topics:
Radiation Oncology • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Yale
Would you extrapolate data from PACIFIC trial for unresectable disease to consider consolidation therapy with durvalumab for Stage III NSCLC with single-station N2 disease amenable to lobectomy?
Answer from: Radiation Oncologist at Academic Institution
I agree with both answers above. The question about adding durvalumab after chemo-RT and lobectomy continues to come up. I would not extrapolate the data from PACIFIC to this situation. First, its important to point out that its not indicated in this situation - the approval for durvalumab in the US...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
No.
Answer from: Medical Oncologist at Academic Institution
I would not. There are enough ongoing trials looking at this question (the largest ongoing, nearly complete accrual being the ECOG ACRIN ANVIL trial) that outside of a clinical trial setting, I would not offer adjuvant durvalumab to fully resected patients. That being said I strongly and...
Answer from: Medical Oncologist at Community Practice
This is a very challenging situation. The obvious textbook answer is no. A couple of important clinical factors come into play. The most important being the patient’s age. For young, healthy, fit patients, a more aggressive approach including lobectomy with mediastinal lymph node dissection, f...